Matinas BioPharma (NYSEMKT: MTNB)
Matinas BioPharma Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Matinas BioPharma Company Info
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.
News & Analysis
Why Matinas BioPharma Stock Crashed Today
The company reported disappointing clinical results.
Why Matinas BioPharma Holdings Shot Almost 28% Higher Today
The proposed brand name for its leading pipeline drug got an important nod.
Here's Why Matinas Biopharma Shares Fell as Much as 23.6% Today
The company announced the pricing of a public stock offering.
Here's Why Matinas BioPharma Shares Lost as Much as 16.9% Today
The small-cap pharma sank on an update from its top competitor.
Why Matinas BioPharma Tumbled 13.4% Today
Good news for its competitor Amarin has investors nervous about Matinas' cardiovascular disease drug MAT9001.
Here's Why Matinas BioPharma Holdings Inc. Is Losing Ground Today
Matinas BioPharma's lead candidate failed to hit the mark in a mid-stage trial.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.